Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of ALT001 in patients with sequelae of ischemic stroke
CTR20263432Phase 2Active
- Sponsor
- Darwin Biotechnology
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALT001 in ischemic stroke, sponsored by Darwin Biotechnology. Started Sep 2026; status: active.
02
Drugs
ALT001
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20263432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263432.